• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ABBOTT MEDICAL SJM TRIFECTA VALVE; HEART-VALVE, NON-ALLOGRAFT TISSUE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ABBOTT MEDICAL SJM TRIFECTA VALVE; HEART-VALVE, NON-ALLOGRAFT TISSUE Back to Search Results
Catalog Number UNK SJM TRIFECTA VALVE
Device Problems Device Stenosis (4066); Central Regurgitation (4068)
Patient Problems Aortic Valve Stenosis (1717); Arrhythmia (1721); Stroke/CVA (1770); Hemorrhage/Bleeding (1888); Myocardial Infarction (1969); Renal Failure (2041); Cardiac Tamponade (2226); Aortic Valve Insufficiency/ Regurgitation (4450); Unspecified Tissue Injury (4559)
Event Date 12/01/2017
Event Type  Injury  
Manufacturer Narrative
Literature article: procedural and one-year outcomes of the basilica technique in europe: the multicentre euro-basilica registry summarized patient outcomes/complications of bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction (basilica) in patients at high risk for coronary artery obstruction (cao) undergoing transcatheter aortic valve implantation (tavi) in a multicentre european registry (euro-basilica) were reported in a research article "procedural and one-year outcomes of the basilica technique in europe: the multicentre euro-basilica registry" in a subject population with multiple co-morbidities including coronary artery disease, prior percutaneous intervention, prior coronary artery bypass surgery, hypertension, diabetes mellitus, peripheral artery disease, prior myocardial infarction, prior stroke, pacemaker implant/implantable cardioverter defibrillator, pulmonary hypertension, kidney disease/injury, liver cirrhosis, oral anticoagulant, and aortic stenosis/regurgitation.Some of the complications reported were aortic stenosis, aortic regurgitation, degeneration, stroke, bleeding, rehospitalization, pacemaker implant, surgical intervention, cardiac tamponade, acute kidney injury, myocardial infarction, unspecified tissue injury, arrhythmia; these complications are anticipated for the procedure and subject population.A more comprehensive assessment could not be performed as the event was non-contemporaneously reported through a literature review and no device or individual patient information was received for analysisna.
 
Event Description
The article, "procedural and one-year outcomes of the basilica technique in europe: the multicentre euro-basilica registry", was reviewed.The article presented a retrospective, multicenter study to evaluate the procedural and one-year outcomes of bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction (basilica) in patients at high risk for coronary artery obstruction (cao) undergoing transcatheter aortic valve implantation (tavi) in a multicentre european registry (euro-basilica).Devices included in this study were evolut r, sapien 3, corevalve, perimount, hancock, inspiris reselia, mitroflow, trifecta, freestyle, freestyle-solo, toronto, elan, and cryolife homograft.The article concluded that euro-basilica is the first multicentre study evaluating the basilica technique in europe.The technique appeared feasible and effective in preventing tavi-induced cao, and one-year clinical outcomes were favourable.The residual risk for cao requires further study.[the primary and corresponding author was mohamed abdel-wahab, heart center leipzig, university of leipzig, leipzig, germany, with corresponding email: mohamed.Abdel-wahab@medizin.Uni-leipzig.De] the time frame of the study was from december 2017 to october 2021.A total of 76 patients were included in the study, of which 18 (23.7%) received an abbott device.The average age was 79 years and the average gender was female.Comorbidities included coronary artery disease, prior percutaneous intervention, prior coronary artery bypass surgery, hypertension, diabetes mellitus, peripheral artery disease, prior myocardial infarction, prior stroke, pacemaker implant/implantable cardioverter defibrillator, pulmonary hypertension, kidney disease/injury, liver cirrhosis, oral anticoagulant, and aortic stenosis/regurgitation.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
SJM TRIFECTA VALVE
Type of Device
HEART-VALVE, NON-ALLOGRAFT TISSUE
Manufacturer (Section D)
ABBOTT MEDICAL
5050 nathan lane n
plymouth MN 55442
Manufacturer (Section G)
ST. JUDE MEDICAL #3014918977
edificio #44 calle 0, ave. 2
el coyol alajuela 1897- 4050
CS   1897-4050
Manufacturer Contact
karen krouse
5050 nathan lane n
plymouth, MN 55442
6517565400
MDR Report Key18668624
MDR Text Key334906826
Report Number2135147-2024-00575
Device Sequence Number1
Product Code LWR
Combination Product (y/n)N
Reporter Country CodeGM
PMA/PMN Number
P100029
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Literature,Health Professional
Reporter Occupation Physician
Type of Report Initial
Report Date 02/08/2024
1 Device was Involved in the Event
Date FDA Received02/08/2024
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Catalogue NumberUNK SJM TRIFECTA VALVE
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received01/17/2024
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
-
-